Intuitive Surgical Has +35% Upside: A Compelling Buy Story Before July 16
Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) looks compelling ahead of its July 16 earnings report, and the setup rarely gets this clean for a category leader trading well below fair value. Shares sit at $413.58, down 26.71% YTD, while…
Intuitive Surgical (NASDAQ:ISRG | ISRG Price Prediction) looks compelling ahead of its July 16 earnings report, and the setup rarely gets this clean for a category leader trading well below fair value. Shares sit at $413.58, down 26.71% YTD, while the 247 base-case target of $559.79 implies 35.35% upside. Wall Street sits higher still at $563.35, with 22 buy ratings against 2 sell.
Three Reasons the Decision Is Easy
Operating momentum is accelerating: Q1 2026 delivered non-GAAP EPS of $2.50 versus a $2.11 consensus (an 18.66% beat) on revenue of $2.77 billion, up 23% year over year. That is the fourth straight beat, following surprises of 13.22%, 20.65%, and 11.95%. Operating income jumped 47.95%. Da Vinci procedures grew ~16% and Ion procedures grew ~39%.
The moat is measurable: The installed base sits at 11,395 da Vinci systems and 1,041 Ion systems, generating $1.69 billion in Q1 instruments and accessories revenue. That is the recurring razor-and-blade annuity retirement portfolios want, on a business that crossed $10 billion in full-year revenue for the first time in FY2025.
Capital return with a fortress balance sheet: ISRG holds $7.98 billion in cash (up 210% YoY) and repurchased 2.3 million shares for $1.1 billion in Q1 alone.
Better Than the Obvious Alternative
Medtronic (NYSE:MDT) is the name investors reach for when they want robotic-surgery exposure with a dividend. ISRG wins the head-to-head decisively. Medtronic’s Hugo platform has limited traction against ISRG’s 11,395-system installed base, and ISRG’s 23% revenue growth operates in a different tier than MDT’s mature medtech mix. For a retirement account that wants compounding, ISRG’s FY2025 operating income growth of 25.4% settles it.
The Catalyst Is Days Away
Polymarket assigns a 97% combined probability that Q2 da Vinci procedure growth prints between 12.5% and 17.5%, sitting inside management’s 13.5% to 15.5% full-year guide. Composite sentiment reads 68.39, bullish. Q3 2025’s earnings day produced a 13.89% single-session gain after a 20.65% surprise. History has favored shares heading into the report.
ISRG shares look well-positioned heading into the July 16 report.
Contact [email protected] for any questions or corrections.
Joel South covers large-cap stocks, dividend investing, and major market trends, with a focus on earnings analysis, valuation, and turning complex data into actionable insights for investors.
He brings more than 15 years of experience as an investor and financial journalist, including 12 years at The Motley Fool, where he served as an investment analyst, Bureau Chief, and later led the Fool.com investing news desk. He has also co-hosted an investing podcast and appeared across TV and radio discussing market trends.
